BioCryst Pharmaceuticals announced on January 23 2026 that it has closed its $700 million acquisition of Astria Therapeutics, Inc., adding Astria’s late‑stage plasma kallikrein inhibitor navenibart to its product line and an early‑stage atopic dermatitis program, STAR0310, to its pipeline.
The deal was financed with a combination of cash on hand and a $396.6 million draw from a Blackstone‑managed credit facility. In exchange, Astria’s equity holders received approximately 37.3 million shares of BioCryst common stock, diluting existing shareholders but providing a strategic equity stake in the combined company.
Navenibart, a monoclonal antibody that inhibits plasma kallikrein, is designed for prophylaxis of hereditary angioedema and can be dosed every three to six months. This dosing advantage positions it as a less burdensome alternative to current injectables such as Takeda’s Takhzyro, which requires injections every two to four weeks.
The acquisition complements BioCryst’s existing oral HAE therapy, ORLADEYO, creating a comprehensive HAE franchise that offers both oral and injectable prophylaxis. By covering the full spectrum of patient preferences, BioCryst aims to capture a larger share of the HAE market and drive double‑digit revenue growth in the coming years.
Financially, the transaction strengthens BioCryst’s balance sheet through the use of cash and a credit facility, while the share issuance provides Astria’s founders and investors with a stake in a company with a proven commercial platform. The deal is expected to generate incremental revenue from navenibart once it reaches the market, while the early‑stage STAR0310 program will be evaluated for strategic alternatives such as partnership or divestiture.
BioCryst’s CEO, who emphasized the strategic fit, said, “Adding navenibart to our portfolio gives us a unique dual‑mode HAE offering that meets unmet patient needs and positions us to lead the market.” The company also welcomed Astria co‑founder Jill C. Milne to its board, reinforcing its rare‑disease expertise.
In 2025, BioCryst’s ORLADEYO generated preliminary, unaudited net revenue of $563 million, a 43% year‑over‑year increase, and total revenue of $601 million, surpassing prior guidance. The strong performance of ORLADEYO underpins the company’s confidence in pursuing the acquisition and supports its outlook for continued growth.
The STAR0310 atopic dermatitis program, acquired in the same transaction, will be explored for strategic alternatives. BioCryst has indicated it will evaluate partnership or divestiture options to maximize value from the program while focusing resources on its core HAE portfolio.
Overall, the completion of the Astria acquisition marks a significant milestone for BioCryst, expanding its therapeutic reach, reinforcing its leadership in rare diseases, and setting the stage for accelerated growth in the hereditary angioedema market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.